Literature DB >> 10446984

Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice.

E Tartour1, F Fossiez, I Joyeux, A Galinha, A Gey, E Claret, X Sastre-Garau, J Couturier, V Mosseri, V Vives, J Banchereau, W H Fridman, J Wijdenes, S Lebecque, C Sautès-Fridman.   

Abstract

Interleukin (IL) 17 is a proinflammatory cytokine secreted mainly by activated human memory CD4 T cells that induces IL-6, IL-8, and nitric oxide. Because IL-6 and IL-8 have been implicated in the pathogenesis of cervical cancer, we investigated the action of IL-17 on human cervical tumor cell lines in vitro and in vivo. We showed that in vitro, IL-17 increases IL-6 and IL-8 secretion by cervical carcinoma cell lines at both protein and mRNA levels. No direct effect of IL-17 on in vitro proliferation of cervical tumor cell lines could be demonstrated. However, two cervical cell lines transfected with a cDNA encoding IL-17 exhibited a significant increase in tumor size as compared to the parent tumor when transplanted in nude mice. This enhanced tumor growth elicited by IL-17 was associated with increased expression of IL-6 and macrophage recruitment at the tumor site. A potential role of IL-17 in modulation of the human cervical tumor phenotype was also supported by its expression on the cervical tumor in patients with CD4 infiltration. IL-17 therefore behaves like a T-cell-specific cytokine with paradoxical tumor-promoting activity. This may partially explain previous reports concerning the deleterious effect of CD4 T cells in cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446984

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  109 in total

1.  The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas.

Authors:  Lubin Qiu; Dongsheng He; Xiang Fan; Zhi Li; Chuangxin Liao; Yonghong Zhu; Haijun Wang
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

Review 2.  Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?

Authors:  Martin J Cannon; Hannah Goyne; Pamela J B Stone; Maurizio Chiriva-Internati
Journal:  Expert Opin Biol Ther       Date:  2011-01-28       Impact factor: 4.388

3.  Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.

Authors:  Maria de la Luz Garcia-Hernandez; Hiromasa Hamada; Joyce B Reome; Sara K Misra; Michael P Tighe; Richard W Dutton
Journal:  J Immunol       Date:  2010-03-17       Impact factor: 5.422

Review 4.  Up for Mischief? IL-17/Th17 in the tumour microenvironment.

Authors:  E Maniati; R Soper; T Hagemann
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

5.  Sodium channel γENaC mediates IL-17 synergized high salt induced inflammatory stress in breast cancer cells.

Authors:  Suneetha Amara; Michael T Ivy; Elbert L Myles; Venkataswarup Tiriveedhi
Journal:  Cell Immunol       Date:  2015-12-19       Impact factor: 4.868

Review 6.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

Review 7.  Immunobiology of hepatocarcinogenesis: Ways to go or almost there?

Authors:  Pavan Patel; Steven E Schutzer; Nikolaos Pyrsopoulos
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

Review 8.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  IL-17RC: a partner in IL-17 signaling and beyond.

Authors:  Allen W Ho; Sarah L Gaffen
Journal:  Semin Immunopathol       Date:  2009-12-13       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.